SlideShare ist ein Scribd-Unternehmen logo
1 von 25
PEDIATRIC MEDICATION
Ravish Yadav
Contents • Introduction
• Importance Of Pediatric Drug Handling
• The Normal Child
Pharmacokinetic of Children
A, D, M, E
Monitoring Parameters
Drug Therapy in Children
Dose Calculation
Appropriate Dosage form and route
Diseases condition
Adverse reaction in Therapy
2
Introduction
3
• Pediatric means..
• As per ICH (2000) ,Childhood is divided in..
Age:- Up to 28
days
(Neonate)
Age:- 2- 11
years
(Children)
Age:- 1- 24
months
(Infants)
Age:- 12-18 years
(Adolescents)
Pharmacokinetics:
• There is high importance of clinical pharmacokinetics in
optimization of drug therapy.
• Drugs that are safe and effective in one group of
pediatric patients may be ineffective or toxic in
another, so an understanding of variability in drug
disposition is essential if children are to receive
rational and appropriate drug therapy.
4
A
D
M
EABSORBTION
DISTRIBUTION
METABOLISM
EXCRETION
• Two factors affecting the absorption of drugs from the
G.I. tract are pH-dependent passive diffusion and gastric
emptying time. Other is G.I. tract enzyme activity.
5
PH
• Premature Infants- Elevated pH (More
than Infant)
• Infant- Range from 6-8
Gastric
Emptying
• Infants/Noenate:- Prolonged gastric
emptying time. But lower peristaltic
movement than older child and adults.
A
• In premature infants, higher serum concentrations of
acid-labile drugs—such as penicillin, ampicillin and
nafcillin—and lower serum concentrations of a weak
acid such as phenobarbital can be explained by higher
gastric pH.
• Gastric emptying time:-
• Gastric emptying time is delayed in infants and
reaches adult levels by 6 to 8 months of age.
• Drugs that are absorbed primarily in the stomach may
be absorbed more completely than anticipated. In the
case of drugs absorbed in the small intestine,
therapeutic effect may be delayed.
6
A
• Gastrointestinal enzyme activities:-
• It is lower in the newborn than in the adult. Activities of
amylase and lipase, beta-glucuronidase, and glutathione
peroxidase enzymes are low in infants up to 4 months of
age.
• Absorption from Intramuscular route:-
• less predictable absorption in infant
• Examples like Diazepam Rapid Absorption ,
Phenobarbital Poor absorption
7
A
• Absorption from Skin :-
• Percutaneous absorption may be increased in neonate
because of an underdeveloped epidermal barrier (stratum
corneum) and increased skin hydration.
• Absorption from Rectal route :-
• The rectal route of administration can be useful in
infants or children who are unable to take oral
medication.
• The mechanism of rectal route absorption is probably
similar to that of the upper part of GI tract, despite
differences in pH, surface area and fluid content.
8
A
• Drug distribution is determined by
• Physicochemical properties of the drug itself (pKa, molecular
weight, partition coefficient,etc…)
• Physiologic factors specific to the patient.
• So, variable aspect is the physiologic functions such
as
• Total Body Water
• Plasma Protein binding of drug
• Volume of Distribution
9
D
10
D
Total Body
Water
• 94% in the fetus, 85% in premature
infants, 78% in full-term infants, and
60% in adults.
Plasma
Protein
Binding
• Less in Newborn and infants
VD
• The decrease in plasma protein binding
of drugs can increase their apparent
volumes of distribution
• Drug metabolism is substantially slower in infants
compared with older children and adults.
• Less maturation of various pathways of metabolism
within a infant.
• E.g. :- sulfation pathway is well developed but the
glucuronidation pathway is undeveloped in infants.
• The cause of the tragic chloramphenicol-induced
gray baby syndrome in newborn infants is a
decreased metabolism of chloramphenicol by
glucuronyl transferases to the inactive glucuronide
metabolite.
11
M
• Because of decreased metabolism, doses of such
drugs as theophylline, phenobarbital, phenytoin, and
diazepam should be decreased in premature infants.
12
M
• The processes of glomerular filtration, tubular
secretion, and tubular reabsorption determine
the efficiency of renal excretion. These
processes may take several weeks to 1 year after
birth to develop fully.
• Glomerular filtration rate is about 2–4 mL/min
• In infants, if possible then avoid Chloramphenicol
and Amino glycoside, because their metabolites
are accumulated due to immature function of
kidney.
13
E
14
Drug therapy in pediatrics
1. Dose calculation
2. Choice of dosage form
3. Disease Condition
4. Adverse reaction
5. Counseling
1. Dose calculation :-
• Height and Wt growth are rapidly changing
factors in childhood, which also influence
significantly some p’kinetic parameters. So, this
factors should be considered during therapy. So
dose calculation is needed.
• Doses should be obtained from pediatric book
for children.. For example, In india IAP-Drug
formulary is reliable source for pediatric
practice and their important drugs.
• For many years, pediatric dosage calculations
used pediatric formulas such as Fried’s rule,
Young’s rule, and Clark’s rule. These formulas are
based on the weight of the child in pounds, or on
the age of the child in months, and the normal
adult dose of a specific drug.
15
1) Young’s Rule :- (based on age)
Pediatric dose =
Age × Adult Dose
Age + 12
2) Fried’s Rule :- (Age adjustment for infants)
Infant Dose =
Age × Adult Dose
150
3) Clark’s Rule :- (based on body weight)
Pediatric Dose =
Weight × Adult Dose
150
16
2. Choice of Dosage form :-
• Other routes like….
17
Oral Route
• Tablets are less convenient
• Liquid preparation are easy to administer in
accurate dose and to form in desirable dose
by dilution
Parenteral Route:-
• Site of Access
• Safety from fluid overload
• Aware about Excipients
• Dose regimrn selection :-
Factors to be considered when selecting a drug
regimen or rout of administration for a pediatric
patient are…
• Age/Weight/Surface area
• Assess the appropriate dose
• Assess the most appropriate interval
• Assess the route of administration
• Consider the expected response and monitoring parameters
• Interactions
18
19
3. Diseases condition :-
Liver disease :-
• Drugs with a high hepatic extraction ratio (>0.7; such
drugs include morphine, meperidine, lidocaine, and
propranolol).
• Clearance of these drugs is affected by hepatic
blood flow. A decreased hepatic blood flow in the
presence of such disease states as cirrhosis and
congestive heart failure is expected to decrease the
clearance of drugs with high extraction ratios.
• Theophylline clearance may decrease by 45% in a
child with acute viral hepatitis.
20
• Serum drug concentrations should be monitored for
drugs with narrow therapeutic index and eliminated
largely by the kidney (e.g., aminoglycosides and
vancomycin) to optimize therapy in pediatric patients
with renal dysfunction.
• For drugs with wide therapeutic ranges (e.g., penicillins
and cephalosporins), dosage adjustment may be
necessary only in moderate to severe renal failure.
• Renal clearance or rate of elimination is directly
proportional to the glomerular filtration rate, as
measured by endogenous renal creatinine clearance.
21
Renal disease :-
• Drug therapy in pediatric patients with cystic
fibrosis require increased doses of certain drugs.
• Studies have reported a higher clearance of such
drugs as gentamicin, tobramycin, netilmicin,
amikacin, dicloxacillin, cloxacillin, azlocillin,
piperacillin, and theophylline.
22
Cystic Fibrosis:-
• Mechanism is not cleared in adverse effect of many
drugs in child. But it may be due to immature p’kinetic
parameters and some medication errors.
• Some well known adverse effect
• Tetracycline  Teeth brown coloration
• Corticosteroids  Growth suppression in Prepubertal
child.
• Paradoxical hyperactivity in child with phenobarbital
treatment
• Aspirin treatment  Reye’s syndrom (Swelling of liver
and brain)
23
4. Adverse reaction in therapy :-
• Medication errors are also considered as an
important cause of ADRs and should always be
considered as a possible causative factor in
any unexplained situation.
• The incidence of medication errors and the
risk of serious errors occurring in children are
significantly greater than in adults.
24
• Attention should be given to the formulation, taste,
appearance and ease of administration of
treatment.
• The regimen should be simple
• Many health professionals often counsel the
parents only, rather than involving the child in the
counseling process.
• Where possible, treatment goals should be set in
collaboration with the child.
• Studies have shown that parents consider the 8-10
year age groups the most appropriate at which to
start including the child in the counseling process.
25
5. Counseling adherence

Weitere ähnliche Inhalte

Was ist angesagt?

pediatrics pharmacology
pediatrics pharmacologypediatrics pharmacology
pediatrics pharmacologyAzad Haleem
 
Drug therapy in pediatric and geriatric age groups
Drug therapy in pediatric and geriatric age groupsDrug therapy in pediatric and geriatric age groups
Drug therapy in pediatric and geriatric age groupsNaser Tadvi
 
Paediatric drugs, its dose and dosage forms
Paediatric drugs, its dose and dosage formsPaediatric drugs, its dose and dosage forms
Paediatric drugs, its dose and dosage formsAiswarya Thomas
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide sharejavvadhasan
 
Individualization of dosage regimen
Individualization of dosage regimenIndividualization of dosage regimen
Individualization of dosage regimenPARUL UNIVERSITY
 
Drug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsDrug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsViraj Shinde
 
Effect of liver disease on pharmacokinetics
 Effect of liver disease on pharmacokinetics  Effect of liver disease on pharmacokinetics
Effect of liver disease on pharmacokinetics pavithra vinayak
 
Determination of dose and dosing interval
Determination of dose and dosing intervalDetermination of dose and dosing interval
Determination of dose and dosing intervalDr. Ramesh Bhandari
 
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenconversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenpavithra vinayak
 
Pharmacokinetics of drug interaction
Pharmacokinetics of drug interactionPharmacokinetics of drug interaction
Pharmacokinetics of drug interactionDr. Ramesh Bhandari
 
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its applicationClinical pharmacokinetics and its application
Clinical pharmacokinetics and its applicationpavithra vinayak
 
General prescribing guidelines for Pediatrics geriatrics pregnancy lactating...
 General prescribing guidelines for Pediatrics geriatrics pregnancy lactating... General prescribing guidelines for Pediatrics geriatrics pregnancy lactating...
General prescribing guidelines for Pediatrics geriatrics pregnancy lactating...Koppala RVS Chaitanya
 
Geriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients PharmacokineticsGeriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients PharmacokineticsAreej Abu Hanieh
 

Was ist angesagt? (20)

pediatrics pharmacology
pediatrics pharmacologypediatrics pharmacology
pediatrics pharmacology
 
Drug therapy in pediatric and geriatric age groups
Drug therapy in pediatric and geriatric age groupsDrug therapy in pediatric and geriatric age groups
Drug therapy in pediatric and geriatric age groups
 
Paediatric drugs, its dose and dosage forms
Paediatric drugs, its dose and dosage formsPaediatric drugs, its dose and dosage forms
Paediatric drugs, its dose and dosage forms
 
Dosing in childrens
Dosing in childrensDosing in childrens
Dosing in childrens
 
Pediatric Medication
Pediatric MedicationPediatric Medication
Pediatric Medication
 
Drug interactions
Drug interactionsDrug interactions
Drug interactions
 
Drug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide shareDrug dosing in elderly, infant and obese patient slide share
Drug dosing in elderly, infant and obese patient slide share
 
Individualization of dosage regimen
Individualization of dosage regimenIndividualization of dosage regimen
Individualization of dosage regimen
 
Drug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patientsDrug use in paediatric & geriatric patients
Drug use in paediatric & geriatric patients
 
Effect of liver disease on pharmacokinetics
 Effect of liver disease on pharmacokinetics  Effect of liver disease on pharmacokinetics
Effect of liver disease on pharmacokinetics
 
Determination of dose and dosing interval
Determination of dose and dosing intervalDetermination of dose and dosing interval
Determination of dose and dosing interval
 
Designing of dosage regimen
Designing of dosage regimenDesigning of dosage regimen
Designing of dosage regimen
 
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimenconversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
conversion from INTRAVENOUS TO ORAL DOSING----- design of dosage regimen
 
Dosing in elderly
Dosing in elderlyDosing in elderly
Dosing in elderly
 
Pharmacokinetics of drug interaction
Pharmacokinetics of drug interactionPharmacokinetics of drug interaction
Pharmacokinetics of drug interaction
 
Drug therapy in geriatrics
Drug therapy in geriatricsDrug therapy in geriatrics
Drug therapy in geriatrics
 
Clinical pharmacokinetics and its application
Clinical pharmacokinetics and its applicationClinical pharmacokinetics and its application
Clinical pharmacokinetics and its application
 
Dosing in childrens
Dosing in childrensDosing in childrens
Dosing in childrens
 
General prescribing guidelines for Pediatrics geriatrics pregnancy lactating...
 General prescribing guidelines for Pediatrics geriatrics pregnancy lactating... General prescribing guidelines for Pediatrics geriatrics pregnancy lactating...
General prescribing guidelines for Pediatrics geriatrics pregnancy lactating...
 
Geriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients PharmacokineticsGeriatric,obese and pediatric patients Pharmacokinetics
Geriatric,obese and pediatric patients Pharmacokinetics
 

Ähnlich wie Paediatric (pediatrics) medication-drugs therapy in pediatrics

P'kinetics &; drug therapy
P'kinetics  &; drug therapyP'kinetics  &; drug therapy
P'kinetics &; drug therapyHeena Parveen
 
Paediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptxPaediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptx65NidheeshKumarPraba
 
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
Pediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptxPediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptx
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptxAzad Haleem
 
Factors modifying drug actions & effects
Factors modifying drug actions & effectsFactors modifying drug actions & effects
Factors modifying drug actions & effectsEneutron
 
prescribing in paediatrics.pptx
prescribing in paediatrics.pptxprescribing in paediatrics.pptx
prescribing in paediatrics.pptxAraphaMvugalo
 
7 Principles of pediatric pharmacotherapy.pptx
7 Principles of pediatric pharmacotherapy.pptx7 Principles of pediatric pharmacotherapy.pptx
7 Principles of pediatric pharmacotherapy.pptxSani191640
 
Geriatric & Pediatrics Pharmacology
Geriatric & Pediatrics Pharmacology  Geriatric & Pediatrics Pharmacology
Geriatric & Pediatrics Pharmacology Manoj Kumar
 
Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21DrSatyabrataSahoo
 
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptxGENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptxkavitharaninachiya
 
Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Ahmad K
 
Pediatric pharmacology by dr.azad al.kurdi
Pediatric pharmacology by dr.azad al.kurdiPediatric pharmacology by dr.azad al.kurdi
Pediatric pharmacology by dr.azad al.kurdiAzad Haleem
 
Neonatal pediatric-pharmacology
Neonatal pediatric-pharmacologyNeonatal pediatric-pharmacology
Neonatal pediatric-pharmacologydunya
 
Drugs in special conditions 1
Drugs in special conditions 1Drugs in special conditions 1
Drugs in special conditions 1Pravin Prasad
 
Pediatrics, Geriatrics, Pregnancy, Lactation
Pediatrics, Geriatrics, Pregnancy, LactationPediatrics, Geriatrics, Pregnancy, Lactation
Pediatrics, Geriatrics, Pregnancy, LactationBikashAdhikari26
 
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdfTDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdfsamthamby79
 
Medical management of congenital adrenal hyperplasia
Medical management of congenital adrenal hyperplasiaMedical management of congenital adrenal hyperplasia
Medical management of congenital adrenal hyperplasiaAbdulmoein AlAgha
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014vanessawhitehawk
 

Ähnlich wie Paediatric (pediatrics) medication-drugs therapy in pediatrics (20)

Paediatrics
PaediatricsPaediatrics
Paediatrics
 
P'kinetics &; drug therapy
P'kinetics  &; drug therapyP'kinetics  &; drug therapy
P'kinetics &; drug therapy
 
Paediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptxPaediatric Pharmacology Part-2.pptx
Paediatric Pharmacology Part-2.pptx
 
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
Pediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptxPediatric  Pharmacology:Pharmacokinetics and pharmacodynamics  .pptx
Pediatric Pharmacology:Pharmacokinetics and pharmacodynamics .pptx
 
Factors modifying drug actions & effects
Factors modifying drug actions & effectsFactors modifying drug actions & effects
Factors modifying drug actions & effects
 
prescribing in paediatrics.pptx
prescribing in paediatrics.pptxprescribing in paediatrics.pptx
prescribing in paediatrics.pptx
 
Pediatrics
PediatricsPediatrics
Pediatrics
 
7 Principles of pediatric pharmacotherapy.pptx
7 Principles of pediatric pharmacotherapy.pptx7 Principles of pediatric pharmacotherapy.pptx
7 Principles of pediatric pharmacotherapy.pptx
 
Geriatric & Pediatrics Pharmacology
Geriatric & Pediatrics Pharmacology  Geriatric & Pediatrics Pharmacology
Geriatric & Pediatrics Pharmacology
 
Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21Principles of pharmacotherapy in neonates and paediatric population21
Principles of pharmacotherapy in neonates and paediatric population21
 
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptxGENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
GENERAL PRESCRIBING GUIDELINES FOR PAEDIATRIC PATIENTS.pptx
 
Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics Paediatric pharmaco-kinetics
Paediatric pharmaco-kinetics
 
Pediatric pharmacology by dr.azad al.kurdi
Pediatric pharmacology by dr.azad al.kurdiPediatric pharmacology by dr.azad al.kurdi
Pediatric pharmacology by dr.azad al.kurdi
 
Neonatal pediatric-pharmacology
Neonatal pediatric-pharmacologyNeonatal pediatric-pharmacology
Neonatal pediatric-pharmacology
 
Drugs in special conditions 1
Drugs in special conditions 1Drugs in special conditions 1
Drugs in special conditions 1
 
Pediatrics, Geriatrics, Pregnancy, Lactation
Pediatrics, Geriatrics, Pregnancy, LactationPediatrics, Geriatrics, Pregnancy, Lactation
Pediatrics, Geriatrics, Pregnancy, Lactation
 
POSOLOGY.pptx
POSOLOGY.pptxPOSOLOGY.pptx
POSOLOGY.pptx
 
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdfTDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
TDM POINTERS [GERIATIC & PAEDIATRIC PATIENTS].pdf
 
Medical management of congenital adrenal hyperplasia
Medical management of congenital adrenal hyperplasiaMedical management of congenital adrenal hyperplasia
Medical management of congenital adrenal hyperplasia
 
Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014Clinical pharmacology in special populations 2014
Clinical pharmacology in special populations 2014
 

Mehr von Ravish Yadav

Pelletization - classification, advantages,uses, mechanism,equipments
Pelletization - classification, advantages,uses, mechanism,equipmentsPelletization - classification, advantages,uses, mechanism,equipments
Pelletization - classification, advantages,uses, mechanism,equipmentsRavish Yadav
 
Patient compliance with medical advice
Patient compliance with medical advicePatient compliance with medical advice
Patient compliance with medical adviceRavish Yadav
 
Patient counselling by pharmacist
Patient counselling by pharmacistPatient counselling by pharmacist
Patient counselling by pharmacistRavish Yadav
 
Infrared spectrum / infrared frequency and hydrocarbons
Infrared spectrum / infrared frequency  and hydrocarbonsInfrared spectrum / infrared frequency  and hydrocarbons
Infrared spectrum / infrared frequency and hydrocarbonsRavish Yadav
 
Narcotic drugs and psychotropic substances act, 1985
Narcotic drugs and psychotropic substances act, 1985Narcotic drugs and psychotropic substances act, 1985
Narcotic drugs and psychotropic substances act, 1985Ravish Yadav
 
Mucoadhesive drug delivery system
Mucoadhesive drug delivery systemMucoadhesive drug delivery system
Mucoadhesive drug delivery systemRavish Yadav
 
Microencapsulation
MicroencapsulationMicroencapsulation
MicroencapsulationRavish Yadav
 
Medicinal and toilet preparations (excise duties) act, 1995 and rules, 1956
Medicinal and toilet preparations (excise duties) act, 1995 and rules, 1956Medicinal and toilet preparations (excise duties) act, 1995 and rules, 1956
Medicinal and toilet preparations (excise duties) act, 1995 and rules, 1956Ravish Yadav
 
Lipids (fixed oils and fats )
Lipids (fixed oils and fats )Lipids (fixed oils and fats )
Lipids (fixed oils and fats )Ravish Yadav
 
Nucleic acids: structure and function
Nucleic acids: structure and functionNucleic acids: structure and function
Nucleic acids: structure and functionRavish Yadav
 
Krebs cycles or TCA cycles
Krebs cycles or TCA cyclesKrebs cycles or TCA cycles
Krebs cycles or TCA cyclesRavish Yadav
 
beta lactam antibiotics
beta lactam antibioticsbeta lactam antibiotics
beta lactam antibioticsRavish Yadav
 
Anti mycobacterial drugs (tuberculosis drugs)
Anti mycobacterial drugs (tuberculosis drugs)Anti mycobacterial drugs (tuberculosis drugs)
Anti mycobacterial drugs (tuberculosis drugs)Ravish Yadav
 
Anti malarial drugs
Anti malarial drugsAnti malarial drugs
Anti malarial drugsRavish Yadav
 
Nomenclature of heterocyclic compound
Nomenclature of heterocyclic compoundNomenclature of heterocyclic compound
Nomenclature of heterocyclic compoundRavish Yadav
 
Infrared spectroscopy (vibrational rotational spectroscopy)
Infrared spectroscopy (vibrational rotational spectroscopy)Infrared spectroscopy (vibrational rotational spectroscopy)
Infrared spectroscopy (vibrational rotational spectroscopy)Ravish Yadav
 

Mehr von Ravish Yadav (20)

Pelletization - classification, advantages,uses, mechanism,equipments
Pelletization - classification, advantages,uses, mechanism,equipmentsPelletization - classification, advantages,uses, mechanism,equipments
Pelletization - classification, advantages,uses, mechanism,equipments
 
Patient compliance with medical advice
Patient compliance with medical advicePatient compliance with medical advice
Patient compliance with medical advice
 
Patient counselling by pharmacist
Patient counselling by pharmacistPatient counselling by pharmacist
Patient counselling by pharmacist
 
Osmotic systems
Osmotic systemsOsmotic systems
Osmotic systems
 
Opioid analgesics
Opioid analgesicsOpioid analgesics
Opioid analgesics
 
Infrared spectrum / infrared frequency and hydrocarbons
Infrared spectrum / infrared frequency  and hydrocarbonsInfrared spectrum / infrared frequency  and hydrocarbons
Infrared spectrum / infrared frequency and hydrocarbons
 
Neurotransmitters
NeurotransmittersNeurotransmitters
Neurotransmitters
 
Narcotic drugs and psychotropic substances act, 1985
Narcotic drugs and psychotropic substances act, 1985Narcotic drugs and psychotropic substances act, 1985
Narcotic drugs and psychotropic substances act, 1985
 
Mucoadhesive drug delivery system
Mucoadhesive drug delivery systemMucoadhesive drug delivery system
Mucoadhesive drug delivery system
 
Microencapsulation
MicroencapsulationMicroencapsulation
Microencapsulation
 
Medicinal and toilet preparations (excise duties) act, 1995 and rules, 1956
Medicinal and toilet preparations (excise duties) act, 1995 and rules, 1956Medicinal and toilet preparations (excise duties) act, 1995 and rules, 1956
Medicinal and toilet preparations (excise duties) act, 1995 and rules, 1956
 
Lipids (fixed oils and fats )
Lipids (fixed oils and fats )Lipids (fixed oils and fats )
Lipids (fixed oils and fats )
 
Nucleic acids: structure and function
Nucleic acids: structure and functionNucleic acids: structure and function
Nucleic acids: structure and function
 
Nanoparticles
NanoparticlesNanoparticles
Nanoparticles
 
Krebs cycles or TCA cycles
Krebs cycles or TCA cyclesKrebs cycles or TCA cycles
Krebs cycles or TCA cycles
 
beta lactam antibiotics
beta lactam antibioticsbeta lactam antibiotics
beta lactam antibiotics
 
Anti mycobacterial drugs (tuberculosis drugs)
Anti mycobacterial drugs (tuberculosis drugs)Anti mycobacterial drugs (tuberculosis drugs)
Anti mycobacterial drugs (tuberculosis drugs)
 
Anti malarial drugs
Anti malarial drugsAnti malarial drugs
Anti malarial drugs
 
Nomenclature of heterocyclic compound
Nomenclature of heterocyclic compoundNomenclature of heterocyclic compound
Nomenclature of heterocyclic compound
 
Infrared spectroscopy (vibrational rotational spectroscopy)
Infrared spectroscopy (vibrational rotational spectroscopy)Infrared spectroscopy (vibrational rotational spectroscopy)
Infrared spectroscopy (vibrational rotational spectroscopy)
 

Kürzlich hochgeladen

Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Pooja Bhuva
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and ModificationsMJDuyan
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxRamakrishna Reddy Bijjam
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jisc
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxmarlenawright1
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...Poonam Aher Patil
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsTechSoup
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfagholdier
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxEsquimalt MFRC
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024Elizabeth Walsh
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17Celine George
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptxMaritesTamaniVerdade
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfSherif Taha
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfDr Vijay Vishwakarma
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the ClassroomPooky Knightsmith
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfPoh-Sun Goh
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Pooja Bhuva
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibitjbellavia9
 

Kürzlich hochgeladen (20)

Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
Sensory_Experience_and_Emotional_Resonance_in_Gabriel_Okaras_The_Piano_and_Th...
 
Understanding Accommodations and Modifications
Understanding  Accommodations and ModificationsUnderstanding  Accommodations and Modifications
Understanding Accommodations and Modifications
 
Python Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docxPython Notes for mca i year students osmania university.docx
Python Notes for mca i year students osmania university.docx
 
Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)Jamworks pilot and AI at Jisc (20/03/2024)
Jamworks pilot and AI at Jisc (20/03/2024)
 
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptxHMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
HMCS Vancouver Pre-Deployment Brief - May 2024 (Web Version).pptx
 
General Principles of Intellectual Property: Concepts of Intellectual Proper...
General Principles of Intellectual Property: Concepts of Intellectual  Proper...General Principles of Intellectual Property: Concepts of Intellectual  Proper...
General Principles of Intellectual Property: Concepts of Intellectual Proper...
 
Introduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The BasicsIntroduction to Nonprofit Accounting: The Basics
Introduction to Nonprofit Accounting: The Basics
 
Holdier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdfHoldier Curriculum Vitae (April 2024).pdf
Holdier Curriculum Vitae (April 2024).pdf
 
Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024Mehran University Newsletter Vol-X, Issue-I, 2024
Mehran University Newsletter Vol-X, Issue-I, 2024
 
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptxHMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
HMCS Max Bernays Pre-Deployment Brief (May 2024).pptx
 
FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024FSB Advising Checklist - Orientation 2024
FSB Advising Checklist - Orientation 2024
 
How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17How to Create and Manage Wizard in Odoo 17
How to Create and Manage Wizard in Odoo 17
 
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
2024-NATIONAL-LEARNING-CAMP-AND-OTHER.pptx
 
Food safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdfFood safety_Challenges food safety laboratories_.pdf
Food safety_Challenges food safety laboratories_.pdf
 
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdfUnit 3 Emotional Intelligence and Spiritual Intelligence.pdf
Unit 3 Emotional Intelligence and Spiritual Intelligence.pdf
 
Fostering Friendships - Enhancing Social Bonds in the Classroom
Fostering Friendships - Enhancing Social Bonds  in the ClassroomFostering Friendships - Enhancing Social Bonds  in the Classroom
Fostering Friendships - Enhancing Social Bonds in the Classroom
 
Micro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdfMicro-Scholarship, What it is, How can it help me.pdf
Micro-Scholarship, What it is, How can it help me.pdf
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
Beyond_Borders_Understanding_Anime_and_Manga_Fandom_A_Comprehensive_Audience_...
 
Sociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning ExhibitSociology 101 Demonstration of Learning Exhibit
Sociology 101 Demonstration of Learning Exhibit
 

Paediatric (pediatrics) medication-drugs therapy in pediatrics

  • 2. Contents • Introduction • Importance Of Pediatric Drug Handling • The Normal Child Pharmacokinetic of Children A, D, M, E Monitoring Parameters Drug Therapy in Children Dose Calculation Appropriate Dosage form and route Diseases condition Adverse reaction in Therapy 2
  • 3. Introduction 3 • Pediatric means.. • As per ICH (2000) ,Childhood is divided in.. Age:- Up to 28 days (Neonate) Age:- 2- 11 years (Children) Age:- 1- 24 months (Infants) Age:- 12-18 years (Adolescents)
  • 4. Pharmacokinetics: • There is high importance of clinical pharmacokinetics in optimization of drug therapy. • Drugs that are safe and effective in one group of pediatric patients may be ineffective or toxic in another, so an understanding of variability in drug disposition is essential if children are to receive rational and appropriate drug therapy. 4 A D M EABSORBTION DISTRIBUTION METABOLISM EXCRETION
  • 5. • Two factors affecting the absorption of drugs from the G.I. tract are pH-dependent passive diffusion and gastric emptying time. Other is G.I. tract enzyme activity. 5 PH • Premature Infants- Elevated pH (More than Infant) • Infant- Range from 6-8 Gastric Emptying • Infants/Noenate:- Prolonged gastric emptying time. But lower peristaltic movement than older child and adults. A
  • 6. • In premature infants, higher serum concentrations of acid-labile drugs—such as penicillin, ampicillin and nafcillin—and lower serum concentrations of a weak acid such as phenobarbital can be explained by higher gastric pH. • Gastric emptying time:- • Gastric emptying time is delayed in infants and reaches adult levels by 6 to 8 months of age. • Drugs that are absorbed primarily in the stomach may be absorbed more completely than anticipated. In the case of drugs absorbed in the small intestine, therapeutic effect may be delayed. 6 A
  • 7. • Gastrointestinal enzyme activities:- • It is lower in the newborn than in the adult. Activities of amylase and lipase, beta-glucuronidase, and glutathione peroxidase enzymes are low in infants up to 4 months of age. • Absorption from Intramuscular route:- • less predictable absorption in infant • Examples like Diazepam Rapid Absorption , Phenobarbital Poor absorption 7 A
  • 8. • Absorption from Skin :- • Percutaneous absorption may be increased in neonate because of an underdeveloped epidermal barrier (stratum corneum) and increased skin hydration. • Absorption from Rectal route :- • The rectal route of administration can be useful in infants or children who are unable to take oral medication. • The mechanism of rectal route absorption is probably similar to that of the upper part of GI tract, despite differences in pH, surface area and fluid content. 8 A
  • 9. • Drug distribution is determined by • Physicochemical properties of the drug itself (pKa, molecular weight, partition coefficient,etc…) • Physiologic factors specific to the patient. • So, variable aspect is the physiologic functions such as • Total Body Water • Plasma Protein binding of drug • Volume of Distribution 9 D
  • 10. 10 D Total Body Water • 94% in the fetus, 85% in premature infants, 78% in full-term infants, and 60% in adults. Plasma Protein Binding • Less in Newborn and infants VD • The decrease in plasma protein binding of drugs can increase their apparent volumes of distribution
  • 11. • Drug metabolism is substantially slower in infants compared with older children and adults. • Less maturation of various pathways of metabolism within a infant. • E.g. :- sulfation pathway is well developed but the glucuronidation pathway is undeveloped in infants. • The cause of the tragic chloramphenicol-induced gray baby syndrome in newborn infants is a decreased metabolism of chloramphenicol by glucuronyl transferases to the inactive glucuronide metabolite. 11 M
  • 12. • Because of decreased metabolism, doses of such drugs as theophylline, phenobarbital, phenytoin, and diazepam should be decreased in premature infants. 12 M
  • 13. • The processes of glomerular filtration, tubular secretion, and tubular reabsorption determine the efficiency of renal excretion. These processes may take several weeks to 1 year after birth to develop fully. • Glomerular filtration rate is about 2–4 mL/min • In infants, if possible then avoid Chloramphenicol and Amino glycoside, because their metabolites are accumulated due to immature function of kidney. 13 E
  • 14. 14 Drug therapy in pediatrics 1. Dose calculation 2. Choice of dosage form 3. Disease Condition 4. Adverse reaction 5. Counseling
  • 15. 1. Dose calculation :- • Height and Wt growth are rapidly changing factors in childhood, which also influence significantly some p’kinetic parameters. So, this factors should be considered during therapy. So dose calculation is needed. • Doses should be obtained from pediatric book for children.. For example, In india IAP-Drug formulary is reliable source for pediatric practice and their important drugs. • For many years, pediatric dosage calculations used pediatric formulas such as Fried’s rule, Young’s rule, and Clark’s rule. These formulas are based on the weight of the child in pounds, or on the age of the child in months, and the normal adult dose of a specific drug. 15
  • 16. 1) Young’s Rule :- (based on age) Pediatric dose = Age × Adult Dose Age + 12 2) Fried’s Rule :- (Age adjustment for infants) Infant Dose = Age × Adult Dose 150 3) Clark’s Rule :- (based on body weight) Pediatric Dose = Weight × Adult Dose 150 16
  • 17. 2. Choice of Dosage form :- • Other routes like…. 17 Oral Route • Tablets are less convenient • Liquid preparation are easy to administer in accurate dose and to form in desirable dose by dilution Parenteral Route:- • Site of Access • Safety from fluid overload • Aware about Excipients
  • 18. • Dose regimrn selection :- Factors to be considered when selecting a drug regimen or rout of administration for a pediatric patient are… • Age/Weight/Surface area • Assess the appropriate dose • Assess the most appropriate interval • Assess the route of administration • Consider the expected response and monitoring parameters • Interactions 18
  • 20. Liver disease :- • Drugs with a high hepatic extraction ratio (>0.7; such drugs include morphine, meperidine, lidocaine, and propranolol). • Clearance of these drugs is affected by hepatic blood flow. A decreased hepatic blood flow in the presence of such disease states as cirrhosis and congestive heart failure is expected to decrease the clearance of drugs with high extraction ratios. • Theophylline clearance may decrease by 45% in a child with acute viral hepatitis. 20
  • 21. • Serum drug concentrations should be monitored for drugs with narrow therapeutic index and eliminated largely by the kidney (e.g., aminoglycosides and vancomycin) to optimize therapy in pediatric patients with renal dysfunction. • For drugs with wide therapeutic ranges (e.g., penicillins and cephalosporins), dosage adjustment may be necessary only in moderate to severe renal failure. • Renal clearance or rate of elimination is directly proportional to the glomerular filtration rate, as measured by endogenous renal creatinine clearance. 21 Renal disease :-
  • 22. • Drug therapy in pediatric patients with cystic fibrosis require increased doses of certain drugs. • Studies have reported a higher clearance of such drugs as gentamicin, tobramycin, netilmicin, amikacin, dicloxacillin, cloxacillin, azlocillin, piperacillin, and theophylline. 22 Cystic Fibrosis:-
  • 23. • Mechanism is not cleared in adverse effect of many drugs in child. But it may be due to immature p’kinetic parameters and some medication errors. • Some well known adverse effect • Tetracycline  Teeth brown coloration • Corticosteroids  Growth suppression in Prepubertal child. • Paradoxical hyperactivity in child with phenobarbital treatment • Aspirin treatment  Reye’s syndrom (Swelling of liver and brain) 23 4. Adverse reaction in therapy :-
  • 24. • Medication errors are also considered as an important cause of ADRs and should always be considered as a possible causative factor in any unexplained situation. • The incidence of medication errors and the risk of serious errors occurring in children are significantly greater than in adults. 24
  • 25. • Attention should be given to the formulation, taste, appearance and ease of administration of treatment. • The regimen should be simple • Many health professionals often counsel the parents only, rather than involving the child in the counseling process. • Where possible, treatment goals should be set in collaboration with the child. • Studies have shown that parents consider the 8-10 year age groups the most appropriate at which to start including the child in the counseling process. 25 5. Counseling adherence